STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Purchases 259,616 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 259,616 shares of the firm’s stock in a transaction dated Wednesday, February 12th. The stock was acquired at an average cost of $14.96 per share, with a total value of $3,883,855.36. Following the completion of the acquisition, the insider now directly owns 11,137,623 shares in the company, valued at approximately $166,618,840.08. This trade represents a 2.39 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The stock was purchased at an average price of $15.49 per share, for a total transaction of $565,880.68.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The stock was purchased at an average price of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. purchased 21,155 shares of STAAR Surgical stock. The shares were bought at an average price of $21.46 per share, for a total transaction of $453,986.30.
• On Wednesday, December 18th, Broadwood Partners, L.P. purchased 23,000 shares of STAAR Surgical stock. The shares were bought at an average price of $24.33 per share, for a total transaction of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. purchased 53,500 shares of STAAR Surgical stock. The shares were bought at an average price of $24.24 per share, for a total transaction of $1,296,840.00.

STAAR Surgical Price Performance

STAAR Surgical stock opened at $15.35 on Friday. The firm’s 50 day simple moving average is $23.37 and its 200-day simple moving average is $28.97. The company has a market cap of $756.45 million, a P/E ratio of 34.89 and a beta of 0.62. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $52.68.

Wall Street Analysts Forecast Growth

STAA has been the topic of a number of recent analyst reports. Jefferies Financial Group downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday. Stifel Nicolaus dropped their price target on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday. Piper Sandler lowered their price objective on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday. StockNews.com cut shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, Stephens reaffirmed an “equal weight” rating and issued a $28.00 price objective on shares of STAAR Surgical in a research note on Wednesday. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $26.86.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Arcadia Investment Management Corp MI purchased a new position in shares of STAAR Surgical in the third quarter worth approximately $37,000. Quarry LP purchased a new position in shares of STAAR Surgical in the third quarter worth approximately $50,000. Quest Partners LLC purchased a new position in shares of STAAR Surgical in the third quarter worth approximately $128,000. Van ECK Associates Corp increased its position in shares of STAAR Surgical by 12.7% in the third quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock worth $129,000 after acquiring an additional 393 shares in the last quarter. Finally, nVerses Capital LLC grew its position in STAAR Surgical by 78.3% during the third quarter. nVerses Capital LLC now owns 4,100 shares of the medical instruments supplier’s stock valued at $152,000 after purchasing an additional 1,800 shares in the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.